Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?

Imran K. Tailor; Nawal F. Alshehry; Syed Z. Zaidi; Mohammed A. Marei; Ibraheem H. Motabi; Mansour Alfayez; Syed Y. Altaf

doi:10.1016/j.hemonc.2020.08.002

Q3 2023

Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?

Imran K. Tailor · Nawal F. Alshehry · Syed Z. Zaidi · Mohammed A. Marei · Ibraheem H. Motabi · Mansour Alfayez · Syed Y. Altaf

10.1016/j.hemonc.2020.08.002 393 المشاهدات 4 الاقتباسات

الاقتباسات

393

المشاهدات

الملخص غير متوفر لهذا المنشور.

الاستشهاد بهذا المقال (APA)

Imran, K. T., Nawal, F. A., Syed, Z. Z., Mohammed, A. M., Ibraheem, H. M., Mansour, A., Syed, Y. A. (2023). Outcome of Myeloma Patients with COVID-19 on Active Lenalidomide-Based Therapy: Does Lenalidomide Protect From Severe COVID-19?. Hematology/Oncology and Stem Cell Therapy. https://doi.org/10.1016/j.hemonc.2020.08.002

Ghada M. ElGohary; Shahrukh Hashmi; Jan Styczynski; Mohamed A. Kharfan-Dabaja; R · 2022

استشهاد

398

Molecular mediators of breast cancer metastasis

Ragini Yeeravalli; Amitava Das · 2021

استشهاد

388

Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia

Nosha Farhadfar; Ying Li; William S. May; Carolyn Brooke Adams · 2021

استشهاد

392

Acute upper limb ischemia in a patient with COVID-19